Over the last 14 months, I’ve been face-to-face (mask-to-mask when required by the government) with over 350 positive COVID-19 patients.  Thankfully, the majority of these patients only had mild to moderate symptoms of illness. Those with severe or prolonged symptoms were aggressively treated with combinations of antibiotics, steroids, ivermectin and/or hydroxychloroquine.  Our office has seen the whole gambit of symptoms with this virus, but fascinatingly, control of blood sugar and insulin levels has been the key to our patient’s staying healthy and/or recovering quickly.  I’m really not worried about this virus any longer.  I’m worried about the intentional confusion of my patients, of the populous of the country and of the people around the world.

A patient showed up in my office this week with thrombocytopenia (low platelets) and profound fatigue 5 days after receiving COVID vaccination that he felt pressured to get in order to keep his job.   He is not the first to show up with these concerns.

A second patient showed up with identical low platelets and bruising over her body after a positive COVID infection lasting three weeks. Her concern was that everyone around her, including her employer, was telling her she should now be vaccinated for COVID-19.

These are two of many people presenting to medical offices like mine, after being given “medical direction” by their employers and governments without the patient or their doctors fully understanding the potential risks of these therapeutics.  And, we can’t and won’t really know what the risks are until these vaccines have been under clinical trial for at least two years.

I have some serious concerns regarding these COVID-19 vaccines.  I have been openly vocal about COVID-19, masks and vaccine use and many of these concerns in various posts on Youtube, Facebook and Instagram.  Because of this, I have been ridiculed by other physicians, “experts” and people who I thought were trustworthy friends in the field of science, now towing the vaccine line.  But, towing the line or remaining silent would to me be death by 1000 cuts.

As I have stated before, I am NOT an anti-vaxxer. I support new medical interventions which are appropriately developed and deployed, after which safety, efficacy and informed consent can be appropriately given to the patient receiving these treatment.  This support includes vaccines.

My biggest concern with the COVID-19 vaccine is that it has the largest propaganda push I’ve ever seen in the 51 years of my life, being stoked by politicians and pharmaceutical companies around the globe.  This push comes AFTER the U.S. and most countries were no longer under severe threat of being medically overwhelmed, as a majority of the population of the world had been exposed and the worse of the pandemic had abated.

Second, in light of research to the contrary, this push is now being levied upon young children, teenagers and young adults, all of whom have little to no risk of severe illness if they contract COVID-19, assuming they haven’t already been exposed to this virus in the last 14 months.  Most individuals with asymptomatic or mild symptoms generate a highly functional T-cell response.  In fact, 50% of  those who have been exposed to coronavirus formed a T cell (cellular immunity) response without activation of B cell response (humoral immunity) and had no antibody formation  (Li X, Geng M, Peng Y, Meng L, Lu S. J Pharm Anal. Apr 2020; 10(2): 102-108).  We know that those who have had or been exposed to the virus have 2-4 years of T-cell immunity.  You can learn more about effectiveness of recent vaccines, T-cell and B-cell immunity in my coronavirus posts here.

To date, other than the continuously running “ticker tape of death” on CNN and multiple other news stations around the world, no conclusive evidence was presented to any of us in the medical community that an actual emergency still existed requiring emergent authorization of three vaccines – all three vaccines have yet to complete Phase IV clinical trials.

After 14 months, COVID-19 has a 99.7% survival rate.  95% of all COVID-19 deaths have comorbid conditions associated with the severity of the infection.  And, the average age of those dying with COVID-19 is 78 years old.  This data all comes from the CDC.  Oh, by the way in case you were wondering as you read that information, the global life expectancy for the average women is 75 years old, and for men it is 70 years old.   That doesn’t leave you with any questions, does it?!

I, and many collegues in the medical community, have serious concerns that premature and reckless approval of these COVID-19 vaccines occurred AFTER the severe threat had abated.  We know that the vaccines only decrease the severity of infection, they don’t actually prevent the infection in a statistically large enough group to be curative.   The push and marketing of vaccination with three products that do not actually prevent COVID-19 infection, are not actually curative,  and to date pose greater risks of side effects than any other vaccine on the market constitute “human experimentation” on a world stage.  Additionally, pushing these products from a governmental bully pulpit is propaganda of a dispicable nature.  This push has created situations between employers and employees that violate individual liberties and are violations of the Nuremberg Code.

In February, 2021, an open letter was written to the European Medicines Agency (EMA) by many concerned physicians and scientists from around the world with these an other concerns that have yet to be answered.  Neither the EMA or the CDC has addressed any of these issues for the medical community.  You can find the letter at Doctors For COVID Ethics.

I post a copy of that letter below:

Emer Cooke, Executive Director, European Medicines Agency, Amsterdam, The Netherlands 28 February 2021

Dear Sirs/Mesdames,

FOR THE URGENT PERSONAL ATTENTION OF: EMER COOKE, EXECUTIVE DIRECTOR OF THE EUROPEAN MEDICINES AGENCY

As physicians and scientists, we are supportive in principle of the use of new medical interventions which are appropriately developed and deployed, having obtained informed consent from the patient. This stance encompasses vaccines in the same way as therapeutics. We note that a wide range of side effects is being reported following vaccination of previously healthy younger individuals with the gene-based COVID-19 vaccines. Moreover, there have been numerous media reports from around the world of care homes being struck by COVID-19 within days of vaccination of residents. While we recognize that these occurrences might, every one of them, have been unfortunate coincidences, we are concerned that there has been and there continues to be inadequate scrutiny of the possible causes of illness or death under these circumstances, and especially so in the absence of post-mortems examinations. In particular, we question whether cardinal issues regarding the safety of the vaccines were adequately addressed prior to their approval by the European Medicines Agency (EMA). As a matter of great urgency, we herewith request that the EMA provide us with responses to the following issues:

1. 1. 1. Following intramuscular injection, it must be expected that the gene-based vaccines will reach the bloodstream and disseminate throughout the body [1]. We request evidence that this possibility was excluded in pre-clinical animal models with all three vaccines prior to their approval for use in humans by the EMA.
      2. If such evidence is not available, it must be expected that the vaccines will remain entrapped in the circulation and be taken up by endothelial cells. There is reason to assume that this will happen particularly at sites of slow blood flow, i.e. in small vessels and capillaries [2]. We request evidence that this probability was excluded in pre-clinical animal models with all three vaccines prior to their approval for use in humans by the EMA.
      3. If such evidence is not available, it must be expected that during expression of the vaccines’ nucleic acids, peptides derived from the spike protein will be presented via the MHC I — pathway at the luminal surface of the cells. Many healthy individuals have CD8-lymphocytes that recognize such peptides, which may be due to prior COVID infection, but also to cross-reactions with other types of Coronavirus [3; 4] [5]. We must assume that these lymphocytes will mount an attack on the respective cells. We request evidence that this probability was excluded in pre-clinical animal models with all three vaccines prior to their approval for use in humans by the EMA.
      4. If such evidence is not available, it must be expected that endothelial damage with subsequent triggering of blood coagulation via platelet activation will ensue at countless sites throughout the body. We request evidence that this probability was excluded in pre-clinical animal models with all three vaccines prior to their approval for use in humans by the EMA.
      5. If such evidence is not available, it must be expected that this will lead to a drop in platelet counts, appearance of D-dimers in the blood, and to myriad ischemic lesions throughout the body including in the brain, spinal cord and heart. Bleeding disorders might occur in the wake of this novel type of DIC-syndrome including, amongst other possibilities, profuse bleedings and hemorrhagic stroke. We request evidence that all these possibilities were excluded in pre-clinical animal models with all three vaccines prior to their approval for use in humans by the EMA.
      6. The SARS-CoV-2 spike protein binds to the ACE2 receptor on platelets, which results in their activation [6]. Thrombocytopenia has been reported in severe cases of SARS-CoV-2 infection [7]. Thrombocytopenia has also been reported in vaccinated individuals [8]. We request evidence that the potential danger of platelet activation that would also lead to disseminated intravascular coagulation (DIC) was excluded with all three vaccines prior to their approval for use in humans by the EMA.
      7. The sweeping across the globe of SARS-CoV-2 created a pandemic of illness associated with many deaths. However, by the time of consideration for approval of the vaccines, the health systems of most countries were no longer under imminent threat of being overwhelmed because a growing proportion of the world had already been infected and the worst of the pandemic had already abated. Consequently, we demand conclusive evidence that an actual emergency existed at the time of the EMA granting Conditional Marketing Authorization to the manufacturers of all three vaccines, to justify their approval for use in humans by the EMA, purportedly because of such an emergency.

Should all such evidence not be available, we demand that approval for use of the gene-based vaccines be withdrawn until all the above issues have been properly addressed by the exercise of due diligence by the EMA. There are serious concerns, including but not confined to those outlined above, that the approval of the COVID-19 vaccines by the EMA was premature and reckless, and that the administration of the vaccines constituted and still does constitute “human experimentation”, which was and still is in violation of the Nuremberg Code. In view of the urgency of the situation, we request that you reply to this email within seven days and address all our concerns substantively. Should you choose not to comply with this reasonable request, we will make this letter public.

This email is copied to: Charles Michel, President of the Council of Europe Ursula von der Leyen, President of the European Commission. Doctors and scientists can sign the open letter by emailing their name, qualifications, areas of expertise, country and any affiliations they would like to cite, to Doctors4CovidEthics@protonmail.com

• • • References

[1] Hassett, K. J.; Benenato, K. E.; Jacquinet, E.; Lee, A.; Woods, A.; Yuzhakov, O.; Himansu, S.; Deterling, J.; Geilich, B. M.; Ketova, T.; Mihai, C.; Lynn, A.; McFadyen, I.; Moore, M. J.; Senn, J. J.; Stanton, M. G.; Almarsson, Ö.; Ciaramella, G. and Brito, L. A.(2019).Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines, Molecular therapy. Nucleic acids 15 : 1–11. [2] Chen, Y. Y.; Syed, A. M.; MacMillan, P.; Rocheleau, J. V. and Chan, W. C. W.(2020). Flow Rate Affects Nanoparticle Uptake into Endothelial Cells, Advanced materials 32 : 1906274. [3] Grifoni, A.; Weiskopf, D.; Ramirez, S. I.; Mateus, J.; Dan, J. M.; Moderbacher, C. R.; Rawlings, S. A.; Sutherland, A.; Premkumar, L.; Jadi, R. S. and et al.(2020). Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals, Cell 181 : 1489–1501.e15. [4] Nelde, A.; Bilich, T.; Heitmann, J. S.; Maringer, Y.; Salih, H. R.; Roerden, M.; Lübke, M.; Bauer, J.; Rieth, J.; Wacker, M.; Peter, A.; Hörber, S.; Traenkle, B.; Kaiser, P. D.; Rothbauer, U.; Becker, M.; Junker, D.; Krause, G.; Strengert, M.; Schneiderhan-Marra, N.; Templin, M. F.; Joos, T. O.; Kowalewski, D. J.; Stos-Zweifel, V.; Fehr, M.; Rabsteyn, A.; Mirakaj, V.; Karbach, J.; Jäger, E.; Graf, M.; Gruber, L.-C.; Rachfalski, D.; Preuß, B.; Hagelstein, I.; Märklin, M.; Bakchoul, T.; Gouttefangeas, C.; Kohlbacher, O.; Klein, R.; Stevanović, S.; Rammensee, H.-G. and Walz, J. S.(2020). SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition, Nature immunology. [5] Sekine, T.; Perez-Potti, A.; Rivera-Ballesteros, O.; Strålin, K.; Gorin, J.-B.; Olsson, A.; Llewellyn-Lacey, S.; Kamal, H.; Bogdanovic, G.; Muschiol, S. and et al.(2020). Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19, Cell 183 : 158–168.e14. [6] Zhang, S.; Liu, Y.; Wang, X.; Yang, L.; Li, H.; Wang, Y.; Liu, M.; Zhao, X.; Xie, Y.; Yang, Y.; Zhang, S.; Fan, Z.; Dong, J.; Yuan, Z.; Ding, Z.; Zhang, Y. and Hu, L.(2020). SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19, Journal of hematology & oncology 13 : 120. [7] Lippi, G.; Plebani, M. and Henry, B. M.(2020).Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis, Clin. Chim. Acta 506 : 145–148. [8] Grady, D. (2021). A Few Covid Vaccine Recipients Developed a Rare Blood Disorder, The New York Times, Feb. 8, 2021. Yours faithfully, Professsor Sucharit Bhakdi MD, Professor Emeritus of Medical Microbiology and Immunology, Former Chair, Institute of Medical Microbiology and Hygiene, Johannes Gutenberg University of Mainz (Medical Doctor and Scientist) (Germany and Thailand) Dr Marco Chiesa MD FRCPsych, Consultant Psychiatrist and Visiting Professor, University College London (Medical Doctor) (United Kingdom and Italy) Dr C Stephen Frost BSc MBChB Specialist in Diagnostic Radiology, Stockholm, Sweden (Medical Doctor) (United Kingdom and Sweden) Dr Margareta Griesz-Brisson MD PhD, Consultant Neurologist and Neurophysiologist (studied Medicine in Freiburg, Germany, speciality training for Neurology at New York University, Fellowship in Neurophysiology at Mount Sinai Medical Centre, New York City; PhD in Pharmacology with special interest in chronic low level neurotoxicology and effects of environmental factors on brain health), Medical Director, The London Neurology and Pain Clinic (Medical Doctor and Scientist) (Germany and United Kingdom) Professor Martin Haditsch MD PhD, Specialist (Austria) in Hygiene and Microbiology, Specialist (Germany) in Microbiology, Virology, Epidemiology/Infectious Diseases, Specialist (Austria) in Infectious Diseases and Tropical Medicine, Medical Director, TravelMedCenter, Leonding, Austria, Medical Director, Labor Hannover MVZ GmbH (Medical Doctor and Scientist) (Austria and Germany) Professor Stefan Hockertz, Professor of Toxicology and Pharmacologym, European registered Toxicologist, Specialist in Immunology and Immunotoxicology, CEO tpi consult GmbH. (Scientist) (Germany) Dr Lissa Johnson, BSc, BA(Media) MPsych(Clin) PhD, Clinical Psychologist and Behavioural Scientist, Expertise in the social psychology of atrocity, torture, collective violence and propaganda, former member, professional body Public Interest Advisory Group (Psychologist) (Australia) Professor Ulrike Kämmerer PhD, Associate Professor of Experimental Reproductive Immunology and Tumor Biology at the Department of Obstetrics and Gynaecology, University Hospital of Würzburg, Germany, Trained molecular virologist (Diploma, PhD-Thesis) and Immunologist (Habilitation), Remains engaged in active laboratory research (Molecular Biology, Cell Biology (Scientist) (Germany) Associate Professor Michael Palmer MD, Department of Chemistry (studied Medicine and Medical Microbiology in Germany, has taught Biochemistry since 2001 in present university in Canada; focus on Pharmacology, metabolism, biological membranes, computer programming; experimental research focus on bacterial toxins and antibiotics (Daptomycin); has written a textbook on Biochemical Pharmacology, University of Waterloo, Ontario, Canada (Medical Doctor and Scientist) (Canada and Germany) Professor Karina Reiss PhD, Professor of Biochemistry, Christian Albrecht University of Kiel, Expertise in Cell Biology, Biochemistry (Scientist) (Germany) Professor Andreas Sönnichsen MD, Professor of General Practice and Family Medicine, Department of General Practice and Family Medicine, Center of Public Health, Medical University of Vienna, Vienna (Medical Doctor) (Austria) Dr Wolfgang Wodarg, Specialist in Pulmonary and Bronchial Internal Medicine, Hygiene and Environmental Medicine, Epidemiology, and Public Health; Honorary Member of the Parliamentary Assembly of the Council of Europe and former Head of the Health Committee of the Parliamentary Assembly of the Council of Europe; former Member of Parliament, German Bundestag; Initiator and Spokesman for the study commission ‘Ethics and Law in Modern Medicine’; Author and University Lecturer (Medical Doctor) (Germany) Dr Michael Yeadon BSc (Joint Honours in Biochemistry and Toxicology) PhD (Pharmacology), Formerly Vice President & Chief Scientific Officer Allergy & Respiratory, Pfizer Global R&D; Co-founder & CEO, Ziarco Pharma Ltd.; Independent Consultant (Scientist) (United Kingdom)